Advisor Group’s Audentes Therapeutics, Inc BOLD Stock Holding History

Advisor Group’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-14	Closed	–	–	5574
2019 Q3	$0	Hold	14	–	–	﹤0.01%	5541
2019 Q2	$1K	Buy	+14	New	+$538	﹤0.01%	5186

Other funds holding BOLD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Advisor Group's BOLD Position: Q4 2019 in Review

Advisor Group sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 14 shares.

Advisor Group first reported a position in BOLD in Q2 2019 and held it in 2 quarters. The position peaked at $1K in Q2 2019. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

Advisor Group reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
Advisor Group sold 14 Audentes Therapeutics, Inc shares in Q4 2019.
Advisor Group first reported a position in Audentes Therapeutics, Inc in Q2 2019 and held it in 2 quarters.
Advisor Group's Audentes Therapeutics, Inc position peaked at $1K in Q2 2019.
188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.